– FRANCE, Paris – Ipsen (EPA: IPN | ADR: IPSEY) today announced that David Meek has resigned as the CEO and will step down from the Board of Directors, effective December 31, 2019, to pursue another professional opportunity as President and CEO of FerGene.
Consequently, the Board has decided to appoint Aymeric Le Chatelier, currently CFO as Interim CEO to replace David Meek as of January 1, 2020. The newly-created Office of the CEO comprised of Harout Semerjian, EVP & Chief Commercial Officer, and Richard Paulson, EVP and CEO of Ipsen North America, will work closely with the Interim CEO and the Board of Directors to ensure a smooth transition and deliver its commitment to improving patients’ lives through innovative medicines in Oncology, Neuroscience, Rare Diseases and Consumer Healthcare.
“The Board of Directors would like to thank David for his leadership and service to Ipsen since 2016 and wish him well in his future endeavors,” said Marc de Garidel, Chairman of the Board.
“It has been my honor to work with the great team at Ipsen,” said David Meek. “I am proud of the accomplishments we have achieved together to be one of the fastest-growing companies in our industry.”
The Board has asked the Nominations Committee, chaired by Carol Xueref, to immediately conduct a search process in order to identify the future Chief Executive Officer.
About Aymeric Le Chatelier
Aymeric Le Chatelier was appointed as EVP, CFO at Ipsen in 2014. Aymeric, a graduate from HEC Business School, started his career at Arthur Andersen. He successively executed several roles in finance in France and the United States at Veolia. He then joined Arjowiggins, a leading manufacturer of creative and technical paper, as Group Chief Financial Officer. He was subsequently appointed Financial Director of Enedis and a member of the Management Board.
Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience and Rare Diseases. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.2 billion in 2018, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY).
For more information: https://www.ipsen.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.